A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The phase 1 study is an open label, multi-center, non-randomized, dose escalation and
expansion study designed to assess the safety, tolerability, and immunogenicity of
IMU-201(PD1-Vaxx) as monotherapy in patients with PD-L1 expressing non-small cell lung cancer
(NSCLC).